[6] In all cases, a healthcare provider should evaluate patient history for any contraindication before initiating therapy
According to a publication by Khorram et al., 16 days of evaluation were sufficient to induce a more than 2% increase in lean muscle cell mass
Both offer access to GLP-1 therapy, but they package clinical support and behavior change tools differently, which can meaningfully change the value you get for your money
Retatrutides action on the glucagon receptor means less liver fat, with up to 86% reduction in liver fat observed in trials
Now, there is a lack of large-scale, long-term clinical trials evaluating its safety parameters and productivity in humans for this specific indication
10.1172/jci.insight.134359 JCI Insight 8 DAlessioD